IRC: #techbytes @ Techrights IRC Network: Saturday, March 01, 2025

-TechBytesBot/#techbytes- ( status 403 @ https://www.thelayoff.com/t/1jn2hy3cd )

schestowitz[TR2]

schestowitz[TR2]

Word of mouth by some people on the inside

schestowitz[TR2]

Could me more next week

schestowitz[TR2]

9 hours ago by Anonymous

schestowitz[TR2]

| 1 reaction (+1/-0)

schestowitz[TR2]

Post ID: @hk+1jn2hy3cd

schestowitz[TR2]

schestowitz[TR2]

@gx+1jn2hy3cd --

schestowitz[TR2]

Any link to a news article?

schestowitz[TR2]

http://ipkitten.blogspot.com/2025/02/review-of-ai-patent-drafting-software.html?showComment=1740674296260#c29185175268634258

schestowitz[TR2]

-TechBytesBot/#techbytes-ipkitten.blogspot.com | Review of AI patent drafting software for life sciences: Qatent - The IPKat

schestowitz[TR2]

"RESPONSE BY QATENT CO-FOUNDER 2/2

schestowitz[TR2]

Beyond clients,...</a></h5><blockquote>RESPONSE BY QATENT CO-FOUNDER 2/2<br /><br />Beyond clients, we are looking for partners in this field. Qatent can hyper-specialize Hey Hi (AI) on top of the base brick for specific verticals (e.g. cosmetics, etc).<br /><br />So as a temporary conclusion: please continue considering this market as an emerging market, and please come back to test again. Meanwhile, if you have feature requests,

schestowitz[TR2]

from baby steps to big challenges, come find us and discuss !<br /><br />All the best,<br /><br />François Veltz<br />Qatent Cofounder<br />"

http://ipkitten.blogspot.com/2025/02/review-of-ai-patent-drafting-software.html?showComment=1740656545138#c2165141826495477891

schestowitz[TR2]

-TechBytesBot/#techbytes-ipkitten.blogspot.com | Review of AI patent drafting software for life sciences: Qatent - The IPKat

schestowitz[TR2]

"Thank you for testing qatent and sharing your thoughts.<br /><br />I am one of the two co-founders of qatent (my cofounder is Kim Gerdes, Professor in Computational Linguistics at Paris-Saclay University, and former head of the master track in AI). As a qualified French patent monopoly attorney, I worked for patent monopoly law firms, I.C.B.M. and Roche Diagnostics: I know the very high expectations of my former colleagues in p

schestowitz[TR2]

harma.<br /><br />Please find below some thoughts:<br /><br />- qatent did its computations on all IPC/CPC classes, including C and D. Qatent is workable for chembio but is surely not optimized for this huge and diverse field (at least as of today). But again, it is workable. We focus on the "fundamental" layer, mechanics, software, medical devices, etc. We make steady progress (new release every month in average, so p

schestowitz[TR2]

lease come back and test again!) but there are tons of challenges for this "very basics" layer (e.g. jurisdiction-dependent drafting styles, patentability diagnostics at claims' drafting, handling of consistency, handling of sufficiency of disclosure partly, machine vision to speed-up the description of figures, reference numerals management, etc). <br /><br />- with respect to the generation of claims: they are not fit

schestowitz[TR2]

-for-purpose "out of the box". It lacks the incorporation of business insights (single or multiple providers, etc) and regulatory insights (e.g. mandatory redundancy of systems in medical devices), for example. Maybe this will change in the future. We are working hard to sophisticate this generation of claims, and our next release will likely improve the situation. But please note that today, you can already use the chat

schestowitz[TR2]

bot and reprocess claim sets (e.g. rephrase method claims into system claims, handle product-by-process, handle Markush claims, etc). <br /><br />- the proficiency in the use of chatbots is highly variable amongst our users. A chatbot is like a virtual partner that knows a lot of things (like the skilled person, it knows all patents on earth), but is not proactive (not yet), it will respond only. If asked the right questions, yo

schestowitz[TR2]

u can get amazing value. It is your role as a patent monopoly attorney to dive deeper and deeper. The deeper the question, the better value you extract from the AIs. At qatent, we try to facilitate this extraction but we cannot (and do not want) to automate 100%. We encode the "canonical" best drafting practices, which may be considered as "non-debatable", to guide the Hey Hi (AI) models. This minimal set of ru

schestowitz[TR2]

les is not trivial and we probably can discuss subtleties endlessly. As an aparté, for example, in my opinion, the problem-solution approach shall be encoded by the IP community as a whole, including patent monopoly offices (yes!), not by proprietary systems ... Code was law, now law is code, but who is writing the code ? For chembio, you know better than me that clinical data cannot be faked, that plausibility / credibility of te

schestowitz[TR2]

chnical effects is at stake, etc. Decision G2/21 is super interesting in this view."